Crystal Adam reported option exercise involving 5,000 shares of Tango Therapeutics, Inc. at $2.91 for $14.6k on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
President, R&D
President, R&D
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$14,550Shares × reported price
Shares traded
5,000Common Stock
Price per share
$2.91Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
120,743Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 6:39 PM ET2-day reporting delay
Accession
0001193125-26-461212Code M · Transaction 401279
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Sell5,000$25.00−$125,000Trade 401280
Nov 11, 2026Option exercise5,000$0.00$0Trade 401281
3 transaction rows in this filing. Joint filers share the same rows.

TNGX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TNGX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5.2%1w ago −9.1%1d ago −4.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $25.00 to $25.9999 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F3: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.